Summer Budget Travel Tips from Gadling

AOL Money & Finance

Abbott Labs to pay J&J $1.67 billion from patent lawsuit

Yesterday, pharmaceutical giant Johnson & Johnson (JNJ) said that its patent infringement lawsuit against Abbott Labs (ABT) was successful, with Abbott ordered to pay $1.67 billion because its best-selling drug, Humira, too closely resembles J&J's Remicade. The drugs are intended to treat rheumatoid arthritis by blocking a substance known as TNF, which causes inflammation. According to the Arthritis Foundation, 1.3 million Americans suffer from rheumatoid arthritis, a chronic disease. Abbott Labs sponsors the group's programs specifically related to rheumatoid arthritis.

The verdict leaves Abbott stock in a tenuous position. The healthcare sector has been in the crosshairs lately as concerns about costly medical reform swirl, with the SPDR S&P Pharmaceuticals (XPH) ETF down slightly year-to-date, compared to the nearly 5% gain on the S&P 500. Abbott Labs has underperformed both comparables, and is down 10% year-to-date.

Continue reading Abbott Labs to pay J&J $1.67 billion from patent lawsuit

Serious Money: Five high-yield, safe, diversified stocks

Billions of investment dollars are sitting on the sidelines for fear of entering the market at the wrong time and losing more money after taking a bath last year. However, the market seems to have hit bottom last March and many investors missed the 40% gain from that point to now.

Market prognosticators are spewing out opinions faster than the public can grasp, or understand. I choose to stick with basic fundamental value propositions and ignore the noise.

I have been buying for the past eight months and riding the market waves, good and bad, to huge gains -- so far. Maybe I will be giving some back, maybe not, but I have also been encouraging readers to take something off the table, in several recent posts.

Continue reading Serious Money: Five high-yield, safe, diversified stocks

Medidata ... an Obama IPO?

Bit by bit, the IPO market is picking up steam. And, the latest deal hit the markets today: Medidata (NASDAQ: MDSO).

So far, the shares are up 19% $16.70 (the IPO priced at $14, which was above its $11-$13 price range).

Founded about ten years ago, Medidata develops web-based software for clinical trials management. Obviously, it's a big market opportunity.

Keep in mind that a drug costs more than $1 billion to develop. Oh, and the process can easily go beyond a decade. In other words, it's important to streamline the process.

Continue reading Medidata ... an Obama IPO?

Don't look to high yield stocks for high returns

Stocks are up this year but not everyone is profiting. One reason is that many investors, stung by the market collapse, have been looking for safety by investing in dividend paying stocks. But Richard Moroney, editor of Dow Theory Forecasts, says that investing for yield is a flawed strategy.

Moroney, a chartered financial analyst, points out that while the S&P 1500 Index is up about 16% so far this year, investors in high-yielding stocks (with yields of 4% or more) have a year-to-date return of just 4%. And he says that stocks that do not pay dividends are up an average of 29%.

We spoke with Richard Moroney to find out why this is the case -- and what income investors should do.

Continue reading Don't look to high yield stocks for high returns

Johnson & Johnson: A stock for your child's college fund

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models, who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, Johnson & Johnson (NYSE: JNJ) is worth a review.

The value proposition with Johnson & Johnson 'isn't rocket science,' as they say, even though the business model (obviously) involves a considerable amount of science.

Continue reading Johnson & Johnson: A stock for your child's college fund

Procter & Gamble beats in Q3, had a passable quarter

Procter & Gamble (NYSE: PG) might not have the best growth rates going these days, but truth be told, I thought the company's Q3 report was acceptable given everything that is going on.

Yes, sales declined by 8%, driven by currency effects. Organic sales, however, increased 1%. Earnings per share increased 2% to 84 cents. This beat Wall Street forecasts by four pennies according to this source.

Continue reading Procter & Gamble beats in Q3, had a passable quarter

Johnson & Johnson (JNJ): 'A buy for any portfolio'

"Health-care stocks have been volatile of late, as the prospects for significant healthcare reform are impacting the group," notes Chuck Carlson.

In The DRIP Investor, he explains, "Johnson & Johnson (NYSE: JNJ) has not been immune to the weakness. And while these shares could remain under pressure in the short run, the company's prospects are significantly brighter than the typical health-care stock."

"First, Johnson & Johnson's diversified business portfolio, which includes pharmaceuticals, medical technology, and consumer products, should help to smooth out results and cushion declines in any one area.

Continue reading Johnson & Johnson (JNJ): 'A buy for any portfolio'

Earnings preview: Will Pfizer beat in Q1?

Pfizer (NYSE: PFE), a pharmaceutical entity whose colleagues include Merck (NYSE: MRK), Novartis (NYSE: NVS), and Johnson & Johnson (NYSE: JNJ), will be reporting first-quarter earnings Tuesday. As one has come to expect, the market believes that the company will be experiencing a decline in bottom-line income. The call is for 49 cents per share versus 61 cents per share in the year-ago period.

That's a drop of 20%. That might not sound so hot, but the good news is that Pfizer has a solid recent track record when it comes to beating earnings expectations. So shareholders might be justified in feeling confident about that aspect of the game.

Continue reading Earnings preview: Will Pfizer beat in Q1?

3M misses Wall Street's mark -- sell the stock?

3M (NYSE: MMM) had a not-that-great first quarter. The declines were significant and ugly. First, net sales plunged over 20%. Second, net income on an adjusted basis likewise spiraled out of control, declining over 40% to $0.81 per share. And no, that didn't meet expectations. Wall Street was looking for $0.86 per share. Sorry, gang.

You've got the dollar and the global recession to blame. Currency translations affected sales, and declines in economic activity didn't help much, either. Many people look to 3M as a staunch dividend play. As such, cash flow is important. Unfortunately, the statement of cash flows this quarter was hard to read. Net cash from operations decreased 30%, and free cash flow lost 35% of its value when compared to the year-ago period. Thankfully, there was enough free cash to cover the dividend.

Continue reading 3M misses Wall Street's mark -- sell the stock?

Analyst upgrades, downgrades and initiations: AMZN, RS, JNJ, NFLX ...

Analyst upgrades:
  • Citigroup upgraded Amazon.com (NASDAQ: AMZN) to Buy from Hold on expectations the company's top-line growth rate could be more sustainable than expected and its operating margins could recover given due to less retail discounting. The firm raised its price target on shares to $97 from $65.
  • UBS upgraded King Pharmaceuticals (NYSE: KG) to Buy from Sell based on expectations that Sandoz will settle patent litigation regarding Skelaxin after last weeks settlement of Clarinex with Schering-Plough (SGP).
  • Jefferies upgraded Reliance Steel (NYSE: RS) to Buy from Hold as it believes steel prices and demand are close to near-term bottoms. The firm raised its target on the stock to $44 from $25.
  • Palm (NASDAQ: PALM) was raised to Buy from Neutral at Banc of America/Merrill.
  • Nestle (OTC: NSRGY) was lifted to Neutral from Underweight at JP Morgan.
  • Johnson & Johnson (NYSE: JNJ) was upgraded at Wachovia to Outperform from Market Perform.

Continue reading Analyst upgrades, downgrades and initiations: AMZN, RS, JNJ, NFLX ...

Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Should you invest in low priced biotech stocks like Dendreon?

When a $7 a share biotechnology company like Dendreon Corp. (NASDAQ: DNDN) rockets 200% to over $20 a share in one day, like it did yesterday after reporting successful Phase 3 trials of its prostate cancer drug, investors get interested in any biotech stock under $10.

But before investing in these speculative companies, you should have a clear understanding of how this niche operates. Marketing plays an important role in order for the companies to raise capital, therefore if you are interested in betting on a company's future, you should consider the risk factors and odds of success.

Continue reading Should you invest in low priced biotech stocks like Dendreon?

Closing Bell: Set up profit taking on news (CVX, DNDN, FNM, GS, JNJ)

Today was just a day of selling the news. We had weak retail sales and we had lower than expected PPI data showing no inflation. But after a 5-week straight rally, investors were selling into earnings despite many estimates looking excessively easy to hit.

Here are today's unofficial closing bell levels:

Dow 7,918.11 -139.70 (-1.73%)
S&P 500 841.87 -16.86 (-1.96%)
Nasdaq 1,626.40 -26.91 (-1.63%)

Top Analyst Upgrades
Top Analyst Downgrades

Continue reading Closing Bell: Set up profit taking on news (CVX, DNDN, FNM, GS, JNJ)

Johnson & Johnson (JNJ) posts better than expected earnings

Johnson & Johnson first quarter earningsHealth Care giant Johnson & Johnson (NYSE: JNJ) had its chance to impress Wall Street this morning with its first quarter earnings release, and the company indeed put up better than expected results, pushing shares higher in the premarket.

Analysts had been expecting the company to earn of $1.22 per share, but the company surpassed those estimates, with a reported $1.26 per share for its first quarter. First quarter earnings were also on par with the $1.22 it reported during the first quarter of 2008.

Continue reading Johnson & Johnson (JNJ) posts better than expected earnings

Before the bell: Stocks set for a flat open despite Goldman's earnings

U.S. stock futures were mixed in a narrow range Tuesday morning, indicating Wall Street stocks could have a flat open, despite Goldman Sachs topping earnings estimates. It seems investors are much more concerned about the general earnings season and the grim outlook for corporate results. Some economic data released later this morning, including retail sales and inflation numbers, will also grab investors' attention.

[Update 9:10: Following a downbeat retail sales report, futures have turned lower and Wall Street is headed for a lower open.]

Goldman Sachs (NYSE: GS) reported a larger-than-expected quarterly profit of $1.8 billion after the close on Monday. It also announced plans to sell $5 billion in stock to help repay its $10 billion government loan. Today, two Dow stocks will be reporting earnings, Johnson & Johnson (NYSE: JNJ) and Intel (NASDAQ: INTC).

Continue reading Before the bell: Stocks set for a flat open despite Goldman's earnings

Next Page »

Symbol Lookup
IndexesChangePrice
DJIA-223.328,280.74
NASDAQ-49.201,796.52
S&P 500-26.91896.42

Last updated: July 03, 2009: 11:07 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance